Hospital
Scranton Quincy Hospital Company LLC
Scranton Quincy Hospital Company LLC was paid $4.66M by Medicaid between Jan 2018 and Nov 2022, across 210 billing codes. Its largest line is 99284, emergency room visit (serious) — 19% of everything it billed.
33Billing provider infoSCRANTON QUINCY HOSPITAL COMPANY LLC
SCRANTON, PA 18510
SCRANTON, PA 18510
33aNPI1922376136assigned 12/02/2011
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.66M
24GClaims194,099
24DCodes billed210
24AFirst – last monthJan 2018 – Nov 2022
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#62 of 154
Median peer was paid$2.82M
This provider vs. median1.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LALOR, PAULA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 143 | $13K | |
| 2019 | 687 | $29K | |
| 2020 | 27,131 | $608K | |
| 2021 | 124,641 | $2.95M | |
| 2022 | 41,497 | $1.06M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 10,300 | 9,677 | $899K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 12,827 | 12,377 | $708K |
| G0378 | Hospital observation service, per hour | 7.0% | 321 | 306 | $328K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.1% | 2,221 | 2,123 | $236K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 4.6% | 6,823 | 6,626 | $215K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 974 | 958 | $155K |
| 80053 | Comprehensive metabolic panel | 2.8% | 13,258 | 12,432 | $129K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.4% | 4,476 | 4,223 | $112K |
| X0621 | 2.0% | 449 | 205 | $94K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.6% | 1,003 | 959 | $75K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 1,248 | 1,215 | $72K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.5% | 14,390 | 13,161 | $70K |
198 more codes
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.5% | 6,239 | $68K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 1.5% | 2,254 | $68K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 1,146 | $60K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.3% | 1,582 | $60K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 787 | $59K |
| 84443 | Thyroid stimulating hormone (TSH) | 1.2% | 2,822 | $56K |
| 76818 | 1.0% | 862 | $49K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,799 | $39K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,376 | $38K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,329 | $36K |
| 80061 | Lipid panel | <1% | 2,433 | $30K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,257 | $29K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 749 | $29K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 3,332 | $27K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 502 | $26K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 127 | $26K |
| 76830 | Ultrasound, transvaginal | <1% | 607 | $26K |
| 81001 | <1% | 9,267 | $23K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 293 | $23K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,038 | $22K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 638 | $22K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,012 | $22K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,267 | $22K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 321 | $21K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 28 | $20K |
| 80050 | General health panel | <1% | 488 | $19K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 783 | $19K |
| 71045 | Radiologic examination, chest; single view | <1% | 2,731 | $19K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 567 | $19K |
| 84702 | <1% | 1,176 | $19K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,267 | $17K |
| 84484 | <1% | 2,177 | $16K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 49 | $16K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 245 | $15K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 531 | $14K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 280 | $14K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 793 | $14K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 471 | $14K |
| 86803 | <1% | 723 | $13K | |
| 76801 | <1% | 323 | $12K | |
| 84439 | <1% | 1,531 | $11K | |
| 83690 | <1% | 2,566 | $11K | |
| 76775 | <1% | 244 | $11K | |
| 85027 | <1% | 1,524 | $10K | |
| 93971 | <1% | 154 | $10K | |
| 84703 | <1% | 1,088 | $10K | |
| 86762 | <1% | 486 | $9K | |
| 76642 | <1% | 241 | $9K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 106 | $9K |
| 77066 | Tomosynthesis, mammo | <1% | 105 | $9K |
| 87040 | <1% | 858 | $8K | |
| 88342 | <1% | 217 | $8K | |
| 86850 | <1% | 1,088 | $8K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 251 | $8K |
| 83880 | <1% | 336 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,281 | $8K |
| 84466 | <1% | 491 | $7K | |
| 87807 | <1% | 616 | $7K | |
| 87340 | <1% | 537 | $7K | |
| 82607 | <1% | 634 | $7K | |
| 83735 | <1% | 1,464 | $7K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 158 | $7K |
| 81025 | <1% | 2,222 | $7K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,082 | $7K |
| 71250 | <1% | 141 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,416 | $7K |
| 74018 | <1% | 494 | $6K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 293 | $6K |
| 85730 | <1% | 1,148 | $6K | |
| 85379 | <1% | 624 | $6K | |
| 76536 | <1% | 131 | $6K | |
| 73564 | <1% | 275 | $5K | |
| 82728 | <1% | 472 | $5K | |
| 86901 | <1% | 1,444 | $5K | |
| 86900 | <1% | 1,443 | $5K | |
| 84481 | <1% | 235 | $5K | |
| 73610 | <1% | 299 | $5K | |
| 85610 | <1% | 1,665 | $5K | |
| 72131 | <1% | 75 | $5K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 117 | $5K |
| 87077 | <1% | 382 | $4K | |
| 93970 | <1% | 55 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 31 | $4K |
| 83605 | <1% | 785 | $4K | |
| 72100 | <1% | 225 | $4K | |
| 73630 | <1% | 402 | $4K | |
| 73030 | <1% | 290 | $4K | |
| 83540 | <1% | 491 | $4K | |
| 84100 | <1% | 791 | $4K | |
| 87186 | <1% | 485 | $4K | |
| 86592 | <1% | 920 | $3K | |
| 73130 | <1% | 303 | $3K | |
| 88313 | <1% | 117 | $3K | |
| 82950 | <1% | 444 | $3K | |
| 82043 | <1% | 414 | $3K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 420 | $3K |
| 85384 | <1% | 276 | $2K | |
| 82248 | <1% | 366 | $2K | |
| 73502 | <1% | 147 | $2K | |
| 87081 | <1% | 439 | $2K | |
| 87070 | <1% | 343 | $2K | |
| 86780 | <1% | 146 | $2K | |
| 0225U | <1% | 35 | $2K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,144 | $2K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 51 | $2K |
| 82570 | <1% | 352 | $2K | |
| 81003 | <1% | 729 | $2K | |
| 82105 | <1% | 102 | $2K | |
| 90715 | <1% | 130 | $2K | |
| 84153 | <1% | 89 | $2K | |
| 82746 | <1% | 174 | $2K | |
| 12001 | <1% | 83 | $2K | |
| 59025 | Fetal non-stress test | <1% | 239 | $2K |
| 84550 | <1% | 325 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 39 | $2K |
| 83655 | <1% | 151 | $2K | |
| 86480 | <1% | 19 | $1K | |
| 82805 | <1% | 58 | $1K | |
| 82550 | <1% | 257 | $1K | |
| 12011 | <1% | 30 | $1K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 15 | $1K |
| 87147 | <1% | 341 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,354 | $1K |
| 86038 | <1% | 88 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 46 | $1K |
| 85652 | <1% | 422 | $1K | |
| 70486 | <1% | 13 | $1K | |
| 84146 | <1% | 50 | $1K | |
| 86140 | <1% | 392 | $1K | |
| 82962 | <1% | 842 | $1K | |
| 86618 | <1% | 46 | $1K | |
| 77065 | Tomosynthesis, mammo | <1% | 16 | $983.04 |
| 87486 | <1% | 51 | $965.18 | |
| 83615 | <1% | 149 | $944.82 | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 25 | $934.63 |
| 82951 | <1% | 72 | $931.52 | |
| 73110 | <1% | 94 | $916.08 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 53 | $841.42 |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 51 | $828.81 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 99 | $814.05 |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 28 | $786.60 |
| 85018 | <1% | 289 | $753.09 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 541 | $692.10 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 539 | $682.06 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,022 | $680.88 |
| 80074 | <1% | 12 | $610.83 | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,305 | $609.19 |
| 85014 | <1% | 205 | $593.90 | |
| 84145 | <1% | 28 | $567.45 | |
| T1015 | A visit at a community health center or clinic (one all-in rate) | <1% | 14 | $554.00 |
| 86787 | <1% | 31 | $553.88 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 79 | $553.50 |
| 83021 | <1% | 26 | $500.17 | |
| 82077 | <1% | 160 | $458.64 | |
| 72040 | <1% | 30 | $424.52 | |
| 73590 | <1% | 27 | $383.01 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,963 | $378.06 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 679 | $375.31 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 755 | $360.36 |
| 87209 | <1% | 16 | $327.44 | |
| 86317 | <1% | 15 | $295.45 | |
| 84156 | <1% | 92 | $287.22 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,047 | $236.49 |
| 86704 | <1% | 15 | $217.06 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 338 | $214.71 |
| 84460 | <1% | 28 | $206.57 | |
| 80069 | <1% | 55 | $201.16 | |
| 80076 | <1% | 24 | $199.83 | |
| 80179 | <1% | 65 | $191.52 | |
| 80143 | <1% | 68 | $191.52 | |
| 86430 | <1% | 27 | $191.46 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 926 | $185.13 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 61 | $183.68 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 173 | $182.23 |
| 82150 | <1% | 40 | $166.19 | |
| 82247 | <1% | 22 | $159.08 | |
| 82952 | <1% | 46 | $157.83 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 210 | $142.53 |
| 86769 | <1% | 13 | $135.04 | |
| 73080 | <1% | 12 | $121.95 | |
| 84450 | <1% | 15 | $105.13 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 78 | $104.34 |
| 85007 | <1% | 33 | $99.98 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 93 | $84.73 |
| 87177 | <1% | 14 | $61.52 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 160 | $57.88 |
| 82565 | <1% | 13 | $54.69 | |
| 85041 | <1% | 13 | $42.00 | |
| 87205 | <1% | 12 | $37.15 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 968 | $33.59 |
| 97161 | <1% | 23 | $19.77 | |
| 97165 | <1% | 23 | $15.12 | |
| 97116 | <1% | 35 | $10.46 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 502 | $8.83 |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 20 | $5.39 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 17 | $4.83 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 17 | $0.00 |
| 97535 | Self-care/home management training, each 15 minutes | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLALOR, PAULA (DIRECTOR/DELEGATED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| Roswell Hospital Corporation | Roswell, NM | $41.27M |
| Wesley Health System LLC | Hattiesburg, MS | $37.82M |
| Metro Knoxville Hma LLC | Powell, TN | $28.70M |
| Bullhead City Hospital Corporation | Bullhead City, AZ | $28.54M |
| Iom Health System LP | Fort Wayne, IN | $27.50M |
| ST. Joseph Health System, LLC | Fort Wayne, IN | $25.43M |
| Laredo Texas Hospital Company LP | Laredo, TX | $19.46M |
| Oak Hill Hospital Corporation | Oak Hill, WV | $18.77M |
| Cocke County Hma, LLC | Newport, TN | $18.34M |
| Cleveland Tennessee Hospital Company LLC | Cleveland, TN | $16.31M |
| Jefferson County Hma LLC | Jefferson City, TN | $14.31M |
| Northwest Arkansas Hospitals, LLC | Springdale, AR | $11.46M |
| Petersburg Hospital Company LLC | Petersburg, VA | $11.20M |
| Campbell County Hma, LLC | Lafollette, TN | $10.07M |
| Warsaw Health System LLC | Warsaw, IN | $9.95M |
| Longview Medical Center LP | Longview, TX | $9.29M |
| Moberly Hospital Company LLC | Moberly, MO | $8.61M |
| Crestview Hospital Company, LLC | Crestview, FL | $8.15M |
| Kirksville Missouri Hospital Company, LLC | Kirksville, MO | $7.98M |
| Victoria of Texas LP | Victoria, TX | $7.74M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.